DKSH Management Malaysia Sdn. Bhd., a subsidiary of DKSH Malaysia, has been appointed as the authorized partner and distributor for PeopleBio, a Korean biotechnology company. Through this partnership, early detection for individuals at risk of Alzheimerโs diseases in Malaysia will be facilitated.
Petaling Jaya, Malaysia, June 20, 2024 โ DKSH Business Unit Healthcare, a leading partner for companies seeking to grow their healthcare business in Asia and beyond, is proud to announce a new strategic partnership with PeopleBio, a Korean biotechnology company dedicated to creating technologies regarding Alzheimerโs disease that contribute to the well-being of individuals.ย
Under the agreement, DKSH Malaysia will provide full Market Expansion Services, encompassing importation and customs clearance, Medical Device Authority (MDA) registration, marketing and sales, distribution, as well as invoicing and cash collection. By harnessing DKSH Malaysiaโs deep market knowledge and capillary distribution network, the collaboration will ensure the availability of PeopleBioโs products for the benefit of Malaysian patients.
Sungmin Kang, CEO, President at PeopleBio, shared enthusiasm about the recent collaboration, stating: โWe are thrilled about this new partnership and the strengths that DKSH Management Malaysia Sdn. Bhd. brings to the forefront. We have faith in DKSH Management Malaysia Sdn. Bhd.โs robust regional presence in the medical devices channel to strengthen our productโs commercial footprint and foster sustained growth in this market.โ
Sandeep Tewari, Head Country Management and Vice President, Healthcare, DKSH Malaysia, added: โAt DKSH, our commitment is rooted in enriching peopleโs lives. This collaboration stands as a significant milestone in our mission to facilitate early detection and intervention of Alzheimerโs disease, aligning seamlessly with our dedication to providing healthcare for all.โ
ย
About PeopleBio Korea
Founded in 2002, PeopleBio is a Korean biotechnology company providing a breakthrough pathway in diagnostics of protein misfolding diseases by employing a proprietary platform technology called Multimer Detection System, MDS. In 2018, PeopleBio received the In-Vitro Diagnostic (IVD) medical device approval on its product, and it became the first commercial blood test for Alzheimerโs disease approved by the relevant health authority. Today, the company has secured nationwide coverage of its productโs test service in more than 700 healthcare providers which includes all levels of hospitals from primary clinics to tertiary hospitals and major health checkup centers. www.peoplebio.net
About DKSHย
DKSHโs purpose is to enrich peopleโs lives. For almost 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 29,040 specialists, generating net sales of CHF 11.1 billion in 2023. DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health, and over-the-counter products as well as medical devices. With around 8,140 specialists, the Business Unit generated net sales of CHF 5.6 billion in 2023. www.dksh.com/hecย